A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to evaluate the efficacy of oral calcitonin
(rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral
density at increased risk of fracture. The secondary purpose of this study was to determine
if there is any food effect by comparing the efficacy and safety of oral calcitonin tablets
administered at dinner or at bedtime.